Key points are not available for this paper at this time.
e23082 Background: Venous thromboembolic events (VTE) are a major cause of morbidity and mortality in cancer patients. We aim to investigate the outcome and incidence of acute DVT and PE in prostate cancer compared to all other malignancies. Methods: The National Readmission Database (2016-2020) was utilized to identify all-cause admissions for patients with a history of prostate cancer. A Propensity Score Matching (PSM) model, matched such patients with subjects having any type of other malignancies. Pearson’s x2 test was applied to the PSM-2 matched cohorts to compare outcomes. Results: Among 3. 2 million all-cause hospitalizations of prostate cancer patients, about 3. 3% suffered a VTE. The majority had acute DVT (1. 6%), followed by PE (1. 1%) & DVT with PE (0. 6%). On a propensity-matched & multivariate analysis, patients with prostate cancer have a lower incidence of acute PE (1. 1% vs 1. 9%, aOR: 0. 57), DVT (1. 9% vs 2. 8%, aOR: 0. 65) & combined DVT with PE (0. 6% vs 1%, aOR: 0. 62) p < 0. 001 as compared to other malignancies. Among different VTEs, the mortality was highest for Acute PE (aOR: 2. 69), followed by DVT with PE (aOR: 1. 68) & DVT (aOR: 1. 55) p < 0. 001 in prostate cancer. Resource utilization is also higher in prostate cancer hospitalizations complicated by VTE, with patients suffering a DVT having the highest LOS (9 vs 3 days) & total cost of hospitalization (20, 425 vs 14, 452) p < 0. 001 followed by DVT with PE and only PE p < 0. 05. Interestingly, patients with DVT have higher readmission rates as compared to PE at 30 days (16. 6% vs 13. 5%, p < 0. 001) and subsequently at 90-day intervals. Conclusions: The odds of venous thromboembolism were lower in prostate cancer when compared to all other patients with active cancer. The mortality was highest for PE in this cohort, while healthcare-related burden and readmission rates were higher for DVT. Table: see text
Devarkonda et al. (Sat,) studied this question.